NASDAQ:CORT
Corcept Therapeutics Inc.
Corcept Therapeutics Inc.'s revenue grew 12.8% in fiscal 2025 to $761.4M while operating margin fell to 5.9%, its lowest in 10 years. Free cash flow was $141.8M, 18.6% of revenue, and the diluted share count rose 5.7%.Summary generated from Corcept Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$761.4M
Revenue growth+12.8%
Revenue, 5-yr CAGR+16.6%
Gross margin98.3%
Operating margin5.9%
Net margin13.1%
ROICn/a
Return on equity15.0%
Debt / equityn/a
Free cash flow$141.8M
FCF margin18.6%
Share count change+5.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 366 | 402 | 482 | 675 | 761 |
| Operating income | 124 | 113 | 107 | 137 | 45 |
| Net income | 113 | 101 | 106 | 141 | 100 |
| Free cash flow | 167 | 120 | 127 | 196 | 142 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KDirector or officer change
Sep 23, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KOther events
Jun 17, 2026 - 8-KOther events
Jun 3, 2026 - 8-KDirector or officer change
May 28, 2026